Ignite Creation Date:
2024-05-06 @ 8:10 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06277934
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-29
First Post:
2024-02-01
Brief Title:
A Study of RGT001-075 in Adult Patients With Obesity
Sponsor:
Regor Pharmaceuticals Inc
Organization:
Regor Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 2 Multicenter Randomized Double-Blind Placebo-Controlled Study of RGT001-075 Compared With Placebo in Adult Patients With Obesity or Overweight
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being conducted to evaluate RGT001-075 to help people who are above a healthy weight range to lose weight In this study participants will either get RGT001-075 or a dummy medicine placebo Which treatment participants get is decided by chance Participants need to take RGT001-075 or placebo once every day for 12 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None